Earnings
Q4 Earnings Summary: Eli Lilly and AbbVie Beat, Uber Mixed
Quarterly earnings reveal a mix of positive surprises and challenges, with Eli Lilly and AbbVie beating expectations and Uber facing hurdles.
Total Stories
20
News
LLY
Section
LLY
Market Analysis
Why Is Eli Lilly (LLY) Stock Up Premarket? $2.4B Biotech Acquisition
Eli Lilly shares rose in premarket trading after the company announced a $2.4 billion deal to acquire Orna Therapeutics.
Market Analysis
Why Did Eli Lilly (LLY) Shares Surge Today? Key Factors
Eli Lilly shares surged over 4.5% on analyst upgrades, acquisition rumors involving Ventyx Biosciences, and a new $1.3 billion research partnership.
Market Analysis
Eli Lilly Breaks $1 Trillion Barrier, a First for the Healthcare Industry
Eli Lilly hit a $1 trillion valuation for the first time, becoming the only healthcare company to reach the milestone as demand for its weight-loss drugs…
Earnings
Eli Lilly Delivers Strong Q3 Performance, Raises Earnings Outlook
Eli Lilly’s Q3 2025 revenue jumped 54% to $17.6 billion with adjusted EPS of $7.02, prompting the company to lift its full-year guidance.
Market Analysis
Why LLY Shares Are Sliding in Premarket Trading: Trump’s Remarks Shake Sector
Eli Lilly shares fell over 3% in premarket trading after Trump signaled price cuts for weight loss drugs, sparking concerns over future margins.
Market Analysis
Why are Eli Lilly’s Shares Crashing Today Despite Strong Earnings?
Eli Lilly's stock crashed over 14% despite strong Q2 earnings, as disappointing weight-loss pill trial results overshadowed 38% revenue growth and raised guidance.
Market Analysis
Why are Verve Therapeutics Shares Skyrocketing in Premarket Trading Today?
Eli Lilly is reportedly close to acquiring gene editing partner Verve Therapeutics for up to $1.3 billion.
Market Analysis
NVO vs LLY: Which Pharma Stock is Likely to Do Better in 2025?
Obesity market continues to boom, with Novo Nordisk opening the gates wide open with Wegovy.
Market Analysis
Eli Lilly’s Stock Tumbles as Firm Cuts EPS Guidance Despite Strong Q1
Eli Lilly's stock dropped over 7% after announcing a lowered profit forecast, despite exceeding Q1 expectations.
Market Analysis
Eli Lilly’s Stock Soars After Weight-Loss Pill Competing with Ozempic Shows Promise
Eli Lilly's new weight-loss pill, matches Ozempic in effectiveness.
Earnings
Eli Lilly’s Q4 2024 Revenue Surges by 45% to $13.53 Billion
Eli Lilly and Company (NYSE: LLY) reported a robust revenue growth of 45% in Q4 2024, reaching $13.53 billion, driven by increased volume from key products.
Market Analysis
LLY Stock Rebounds Amid AI-Driven ALS Research Breakthroughs
Verge Genomics and Eli Lilly have made significant progress in their collaboration to develop ALS treatments, identifying two promising drug targets using AI technology.